Article
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2021
Kron Anna, Scheffler Matthias, Heydt Carina, Ruge Lea, Schaepers Carsten, Eisert Anna-Kristina, Merkelbach-Bruse Sabine, Riedel Richard, Nogova Lucia, Fischer Rieke Nila, Michels Sebastian, Abdulla Diana S Y, Koleczko Sophia, Fassunke Jana, Schultheis Anne M, Kron Florian, Ueckeroth Frank, Wessling Gabriele, Sueptitz Juliane, Beckers Frank, Braess Jan, Panse Jens, Grohé Christian, Hamm Michael, Kabitz Hans-Joachim, Kambartel Kato, Kaminsky Britta, Krueger Stefan, Schulte Clemens, Lorenz Joachim, Lorenzen Johann, Meister Wolfram, Meyer Andreas, Kappes Jutta, Reinmuth Niels, Schaaf Bernhard, Schulte Wolfgang, Serke Monika, Buettner Reinhard, Wolf Jürgen
Abstract excerpt
INTRODUCTION: Robust data on the outcome of MET-aberrant NSCLC with nontargeted therapies are limited, especially in consideration of the heterogeneity of MET-amplified tumors (METamp). METHODS: A total of 337 tumor specimens of patients with MET-altered Union for International Cancer Control stage IIIB/IV NSCLC were analyzed using next-generation sequencing, fluorescence in situ hybridization, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.